Why One Drug Company Held Back a Better Drug

The presumptive Democratic Senate nominee from Maine on his controversies, contradictions and pitch for radical change. Thoughts? Email us at theinterview@nytimes.com Watch our show on YouTube: youtube.com/@TheInterviewPodcast For transcripts and more, visit: nytimes.com/theinter ...  Show more

Inside a hospital in Nebraska, 16 Americans who may have been exposed to the hantavirus have begun an unusually long quarantine. In some cases, it will last up to 42 days. Apoorva Mandavilli, who covers global health for The New York Times, explains what is known about the deadly ...  Show more

Between 2006 and 2016, the number of drug patents granted in the United States doubled -- but not because there was an explosion in invention or innovation. Drug companies have learned how to game the system, accumulating patents not for new medicines but for small changes to exi ...  Show more

In the first of two episodes this week, we're taking a deep dive into the pharmaceutical industry.

How much does the medication you take actually cost? What if a company came along and bought the rights to a particular drug and started charging double, triple, or even 1 ...

From the HIV/AIDS crisis, to the opioid epidemic, to the COVID-19 pandemic, pharmaceutical corporations have been accused of profiteering at the expense of countless lives. Nick Dearden, director of Global Justice Now and the author of a new book called <a href="https://www.ve ...

Between 2006 and 2016, the number of drug patents granted in the United States doubled -- but not because there was an explosion in invention or innovation. Drug companies have learned how to game the system, accumulating patents not for new medicines but for small changes to exi ...  Show more